Document:

exv10w3

Exhibit 10.3

AMENDMENT NO. 1

TO INTERCREDITOR AGREEMENTS AND SECURITY AGREEMENT

     AMENDMENT NO. 1 dated as of June 24, 2010 (this “Amendment”) to (x) INTERCREDITOR
AGREEMENT, dated as of May 2, 2008 (as amended, modified or otherwise supplemented from time to
time, the “Bermudian Intercreditor Agreement”) among ACS 2008-1 LIMITED, a Bermuda exempted
company, as borrower (the “Bermudian Borrower”), ACS AIRCRAFT FINANCE IRELAND 3 LIMITED, an Irish
private limited liability company, as guarantor (the “Irish Borrower” who, together with the
Bermudian Borrower, the “Borrowers”), CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK f/k/a Calyon
(New York Branch), a societe anonyme organized under the laws of France, acting through its NEW
YORK BRANCH (the “Facility Agent”, the “Collateral Agent” and the “Liquidity Facility Provider”),
AIRCASTLE ADVISOR LLC, a limited liability company organized under the laws of the State of
Delaware (“AA Delaware”) and DEUTSCHE BANK TRUST COMPANY AMERICAS (“DBTCA”), in its capacity as the
person appointed as operating bank (the “Operating Bank”), (y) INTERCREDITOR AGREEMENT, dated as of
May 2, 2008 (as amended, modified or otherwise supplemented from time to time, the “Irish
Intercreditor Agreement” which, together with the Bermudian Intercreditor Agreement, the
“Intercreditor Agreements”) among the Irish Borrower, as borrower, the Bermudian Borrower, as
guarantor, the Facility Agent, the Collateral Agent, the Liquidity Facility Provider, AA Delaware
and the Operating Bank and (z) SECURITY AGREEMENT, dated as of May 2, 2008 (as amended, modified or
otherwise supplemented from time to time, the “Security Agreement”) among the Irish Borrower, the
Bermudian Borrower, AA Delaware, the additional grantors referred to therein, the Facility Agent,
the Collateral Agent and the Operating Bank.

WITNESSETH:

     WHEREAS, each of the parties hereto are party to the Intercreditor Agreements and, to the
extent required, the Security Agreement;

     WHEREAS, each of the parties hereto have agreed to amend the Intercreditor Agreements and the
Security Agreement in certain respects as provided herein;

     NOW, THEREFORE, in consideration of the premises and for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

     Section 1. Definitions. Unless otherwise defined or provided herein, capitalized
terms used herein have the meanings attributed thereto in the Intercreditor Agreements.

     Section 2. Amendments; Agreements; Etc.

     (a) Amendment to Intercreditor Agreement. The definition of “Adjusted Appraised Value” set
forth in Section 1.01 of the Intercreditor Agreements is hereby amended and restated in its
entirety as follows:

-1-

 

     ““Adjusted Appraised Value” means, as of any Payment Date and in respect of any Aircraft, the
lower of (a) the maintenance adjusted current market value of such Aircraft (plus 75% of (x)
amounts on deposit in the Lessee Funded Account or Maintenance Reserve Account in respect of such
Aircraft and (y) amounts available for drawing under any Qualifying Maintenance LCs issued in
respect of such Aircraft) and (b) the maintenance adjusted base value of such Aircraft (plus 75% of
(x) amounts on deposit in the Lessee Funded Account or Maintenance Reserve Account in respect of
such Aircraft and (y) amounts available for drawing under any Qualifying Maintenance LCs issued in
respect of such Aircraft), in each case as determined in the most recent annual Appraisal prepared
by the Appraiser in accordance with Section 5.03(i) hereof, as each such value (but not such
deposits) shall be reduced by 0.50% for each full month since the date of such Appraisal;
provided that for the purposes of calculating the Required LTV the aggregate amount
of Qualifying Maintenance LCs for the purposes of calculating the Adjusted Appraised Value for all
Aircraft shall not exceed $20,000,000.”

     (b) Amendment to Security Agreement. The definition of “Letter of Credit” set forth in
Section 1.01 of the Security Agreement is hereby amended and restated in its entirety as follows:

     “Letter of Credit” means any (a) “letter of credit” as defined in Section 5-102 of the UCC or
(b) bank guarantee or credit support issued by a Qualifying LC Provider.

     (c) Additions. The following definitions are hereby added to Section 1.01 of the
Intercreditor Agreements:

     ““Qualifying LC Provider” means a reputable banking institution in either the United States or
London, England who shall have a senior, unsecured and unguaranteed long-term dollar-denominated
debt rating of “AA-” from Standard & Poor’s or “Aa3” from Moody’s.”

     ““Qualifying Maintenance LC” means, as of any Payment Date, any irrevocable standby letter of
credit (i) provided under the Lease of an Aircraft to secure the relevant Lessee’s obligations in
respect of maintenance repairs, airworthiness directives and/or redelivery requirements, (ii) in a
customary form, issued under Uniform Customs and Practice for Documentary Credits, (iii) payable in
dollars, (iv) the place of presentment of drafts or demands under which to be in the United States,
London, Frankfurt or Paris, (v) payouts under which to be not subject to withholdings, (vi) in
customary form for standby letters of credit with sight draft and/or sight draw certificate
specifying, inter alia, that a default has occurred under such Lease, (vii) issued or confirmed by
a Qualifying LC Provider, (viii) having an expiry date no earlier than 30 days after such Payment
Date and (ix) with respect to which executed undated originals of all drafts, certificates, powers
of attorney and other documents required to be presented in order to render it practicable for the
Collateral Agent acting alone to procure the honor of such letter of credit shall have been
delivered to the Collateral Agent; provided that the bank guarantees issued by
Fortis Bank (Nederland) N.V. with serial nos. NLEGG006070 and NLEGG004134 under the leases of the
Aircraft with manufacturer’s serial numbers 24066 and 24226, as from time to time extended, shall
also be deemed Qualifying Maintenance LCs if, as of such Payment Date, the Dutch government owns
100% of Fortis Bank (Nederland) N.V. and the senior, unsecured and unguaranteed long-term
dollar-denominated debt obligations of Fortis Bank (Nederland) N.V. are rated A- or higher by
Standard & Poor’s, and clauses (viii) and (ix) above shall be satisfied.”

     Section 3. Delivery of Qualifying Maintenance LCs. The Collateral Agent may at its
option from time to time by notice to the Borrower and the Guarantor request that the original
instruments comprising any or all Qualifying Maintenance LCs be delivered to the Collateral Agent.
Promptly upon such notice, the Borrower and Guarantor shall cause the original instruments
comprising such Qualifying Maintenance LCs to be delivered to the Collateral Agent.

-2-

 

     Section 4. Miscellaneous. Except as otherwise specified in this Amendment, the
Intercreditor Agreements and the Security Agreement shall remain in all respects unchanged and in
full force and effect and is hereby ratified and confirmed; provided, however, in the event of any
conflict between any provisions of the Intercreditor Agreements or the Security Agreement and the
provisions of this Amendment, the provisions of this Amendment shall prevail. From and after the
date of this Amendment, all references to “this Agreement” in the Intercreditor Agreements and in
the Security Agreement shall be deemed to be references to the Intercreditor Agreements or the
Security Agreement, as applicable, as amended by this Amendment.

     By its signature hereto, each of the parties hereto (other than the Operating Bank) hereby
request and direct the Operating Bank to execute and deliver this Amendment and to take any and all
further action necessary or desirable to effect the transactions contemplated hereby.

     Section 5. Incorporation by Reference. Sections 8.02, 8.03, 8.05, 8.08, 8.09, 8.10,
8.11, 8.12, 8.13 and 8.14 of the Intercreditor Agreements are incorporated herein and made
applicable to this Amendment.

[signature pages follow]

-3-

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of
the day and year first above written.

	 	 	 	 	 
	 	ACS 2008-1 LIMITED,

 	 
	 	By  	/s/
Ron Wainshal	 
	 	 	Name:  	Ron Wainshal 	 
	 	 	Title:  	Director 	 
	 

-4-

 

	 	 	 	 	 	 	 

	 	 	SIGNED AND DELIVERED	 	 
	 
	 	 	 	 	 	 
	 	 	On behalf of	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	ACS AIRCRAFT FINANCE IRELAND 3 LIMITED,	 	 
	 
	 	 	 	 	 	 
	 	 	by its duly appointed attorney	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	/s/ Jane  O’Callaghan	 	 
	  

	 	 	 	 

Name: Jane O’Callaghan
	 	  
	 

	 	 	 	Title: Director	 	 
	 
	 	 	 	 	 	 
	 	 	in the presence of:	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	/s/  Taryn Alcala	 	 
	  

	 	 	 	 

Name: Taryn Alcala
	 	  
	 

	 	 	 	Title: Administrator	 	 

-5-

 

	 	 	 	 	 	 	 

	 	 	CREDIT AGRICOLE CORPORATE AND
      INVESTMENT BANK f/k/a
Calyon (New York
      Branch), acting through its NEW YORK BRANCH,

     as the Facility Agent, the Collateral Agent and the
      Liquidity Facility
Provider	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	/s/ Ted Vandermel	 	 
	 

	 	 	 	 

Name: Ted Vandermel
	 	 
	 

	 	 	 	Title: Director	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	/s/ Edward Chu	 	 
	 

	 	 	 	 

Name: Edward Chu
	 	 
	 

	 	 	 	Title: Vice President	 	 

-6-

 

	 	 	 	 	 	 	 

	 	 	AIRCASTLE ADVISOR LLC,

     as the Administrative Agent	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	 	 	 
	 

	 	 	 	/s/ Joseph Schreiner 

Name: Joseph Schreiner
	 	 
	 

	 	 	 	Title: Executive Vice President	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	 	 	 
	 

	 	 	 	/s/ Ron Wainshal 

Name: Ron Wainshal
	 	 
	 

	 	 	 	Title: Chief Executive Officer	 	 

-7-

 

	 	 	 	 	 
	 	DEUTSCHE BANK TRUST COMPANY AMERICAS,

     as the Operating Bank

 	 
	 	By 	/s/ Louis Bodi 	 
	 	 	Name:  	Louis Bodi 	 
	 	 	Title:  	Vice President 	 
	 
	 	By 	/s/ Sue Kim  	 
	 	 	Name:  	Sue Kim 	 
	 	 	Title:  	Associate 	 
	 

-8-

 

	 	 	 	 	 
	 	     
Consented and Agreed:

     [Required Lenders]

 	 
	 	By 	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 	 	 

-9-exv10w2

Exhibit 10.2

EXCLUSIVE LICENSE AGREEMENT

between

OMEROS CORPORATION and HELION BIOTECH

     This license agreement (the “Agreement”) is made effective the 20th day of April 2010 (the
“Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of
business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Helion Biotech ApS,
CVR No. 31758106, having a principal place of business at Egholmvej 10, 2720 Vanløse Denmark
(“Helion”).

     WHEREAS Helion owns certain intellectual property rights related to mannan-binding
lectin-associated serine protease-2 (“MASP-2”); and

     WHEREAS Omeros wishes to undertake an exclusive license in Helion’s intellectual property
rights related to MASP-2; and

     WHEREAS Helion wishes to grant Omeros an exclusive license in Helion’s intellectual property
rights related to MASP-2 in return for potential royalty and milestone payments and sublicense
revenue sharing;

     NOW THEREFORE, in consideration for the mutual covenants and obligations set forth herein as
well as other good and valuable consideration, the parties hereby agree as follows:

	1	 	Key Definitions
	 
	1.1	 	“Initial MASP-2 Patents” shall have the definition set forth in Exhibit A to this
Agreement.
	 
	1.2	 	“Intellectual Property Rights” shall mean all inventions, ideas, discoveries, issued,
reissued or reexamined patents, pending and future patent applications, continuation,
continuation-in-part and divisional patent applications, utility models, inventor’s
certificates, trade secrets, know-how, copyrights and trademarks.
	 
	1.3	 	“Licensed Field” shall mean inhibition of mannan-binding lectin-mediated activation of the
complement system for the prevention, treatment or diagnosis of any disease or condition in
humans or other animals, including, without limitation, through inhibition of mannan-binding
lectin associated serine protease(s) by administering inhibitory antibodies or fragments
thereof or other inhibitors.
	 
	1.4	 	“Licensed IP” shall have mean all of Helion’s Intellectual Property Rights related to MASP-2
within the Licensed Field, which Licensed IP includes, without limitation, the Initial MASP-2
Patents and the Other MASP-2 Patents.
	 
	1.5	 	“Licensed Products” shall mean all antibodies, inhibitors and other products that, were it
not for the license granted by Helion to Omeros under this Agreement, would infringe, or the
use, manufacture, offer for sale or sale of which would infringe, any valid and subsisting
claim(s) of any issued patent within either the Initial MASP-2 Patents or the
Other MASP-2 Patents in the country or countries in which such products are offered for
sale, sold, manufactured or used.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-1-

 

	1.6	 	“Net Enforcement Proceeds” shall mean (a) all awards, judgments, settlements or damages
collected by Omeros from its enforcement of the Licensed IP against third parties, less (b)
all of Omeros’ enforcement and litigation costs and legal fees.
	 
	1.7	 	“Net Sales” shall mean (a) gross monetary amounts invoiced and collected by Omeros for the
sale of Licensed Products (excluding any Sublicense Revenue), less (b) the sum of cash, trade,
or quantity discounts, sales, use, tariff, import/export duties or other excise taxes, and any
other governmental taxes imposed on particular sales, transportation charges and allowances,
commissions to third party sales agents, and credits to customers because of rejections or
returns, plus (c) the Net Enforcement Proceeds. For purposes of this paragraph, the
acquisition of Licensed Products from Omeros as part of an acquisition of all or a substantial
part of the assets of Omeros’ business to which this Agreement pertains shall not be
considered a sale of Licensed Products.
	 
	1.8	 	“Other MASP-2 Patents” shall have the definition set forth in Exhibit B to this
Agreement.
	 
	1.9	 	“Sublicense Revenue” shall mean all sublicense royalties, milestones or other sublicense fees
received by Omeros from third parties for a sublicense under the Initial MASP-2 Patents and/or
the Other MASP-2 Patents for the manufacture, sale or distribution of Licensed Products,
excluding any amounts included in the Net Sales, provided, however that the Sublicense Revenue
shall not include any fees or payments from such third parties to Omeros to support research
and development efforts, to purchase equity in Omeros, for licensing under other intellectual
property not included in the Initial MASP-2 Patents and/or the Other MASP-2 Patents, or for
any other purpose other than as compensation for such sublicense under the Initial MASP-2
Patents and/or the Other MASP-2 Patents.
	 
	2	 	Grant Of License
	 
	2.1	 	Helion hereby grants to Omeros for the term of this Agreement a royalty-bearing, world-wide
exclusive license in and to the Licensed IP within the Licensed Field, including the right to
grant sublicenses thereunder, including, without limitation, all rights for the research,
development, manufacture, use, sale, offering for sale, distribution, exportation and
importation of any and all products and the practice of all methods claimed in or encompassed
by the Licensed IP, including, without limitation, the exclusive right to develop,
manufacture, use, sell, offer for sale, distribute, export and import the Licensed
Products.
	 
	2.2	 	Helion shall also provide to Omeros access to the cell line for Helion’s [†] monoclonal
antibody (the “[†] Antibody”) and all available data for and samples, if available, of all
MASP-2 antibodies owned or controlled by Helion, including, without limitation, the [†]
Antibody (collectively the “Helion Antibodies”), without added compensation to Helion from
Omeros other than reimbursement of Helion’s expenses for providing such access,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

	 	 	on a pass-through basis, and at no expense to Helion. Helion has provided a sample of the [†]
Antibody to Omeros for assessment of its properties. Omeros shall pay to Helion an annual
maintenance fee of [†] ($[†]) (the “Research Exclusivity Fee”), with a first Research
Exclusivity Fee due within [†] of the Effective Date and then within [†] of the anniversary of
the Effective Date annually thereafter, each year during the term of this Agreement for so
long as Omeros wishes to preclude Helion from providing any access to the [†] Antibody to
third parties. If Omeros fail to pay any Research Exclusivity Fee when due or if Omeros
provides Helion written notice that Omeros does not wish to maintain research exclusivity for
the [†] Antibody, then thereafter Helion shall have the right to license out the [†] Antibody
to a third party distributor to sublicense and sell the [†] Antibody to other third parties
provided that such third parties may use the [†] Antibody solely for non-commercial research
purposes only, such use expressly excluding the right to modify, sequence or otherwise develop
the [†] Antibody, provided, however, that such third party license to research use of the [†]
Antibody shall not be construed to include any license under the Licensed IP or under any
other Intellectual Property Rights owned or held by Omeros.
	 
	3	 	Royalties and Sublicense Revenue
	 
	3.1	 	Omeros shall pay Helion on a quarterly basis a royalty as a percentage of Net Sales that were
collected during each quarter of the term of this Agreement, which royalty percentage shall be
determined as either (a) [†] percent ([†]%) of Net Sales for Licensed Products that are
encompassed by any valid and subsisting claim of any patent included in the Initial MASP-2
Patents, or (b) [†] percent ([†]%) of Net Sales for Licensed Products that are encompassed by
any valid and subsisting claim of any patent included in the Other MASP-2 Patents (the
“Royalty”); provided, however, that if the total royalty burden paid by Omeros to all entities
(including Helion and third parties) for licenses to Intellectual Property Rights that are
specifically directed to inhibitors or methods of inhibiting mannan-binding lectin-mediated
activation of the complement system (“Total Royalty Burden”) exceeds [†] percent ([†]%), then
the Royalty shall be reduced by [†] of the difference between the Total Royalty Burden and [†]
percent ([†]%), except that in any event Helion shall be paid a minimum Royalty of either [†]
percent ([†]%) or [†] percent ([†]%) for (a) the Initial MASP-2 Patents or (b) the Other
MASP-2 Patents, respectively. For purposes of clarity, the Total Royalty Burden shall be
computed based on all licensees under Intellectual Property Rights for which Omeros is
required to pay a royalty for the sale of Licensed Products. For purposes of clarity, if a
Licensed Product is encompassed by valid and subsisting claims of patents included in both the
Initial MASP-2 Patents and the Other MASP-2 Patents, than the Royalty shall be computed only
on the basis of the Other MASP-2 Patents.
	 
	3.2	 	Omeros shall pay Helion on a quarterly basis a share (the “Sublicense Share”) of Sublicense
Revenue collected by Omeros during the subject quarter, which Sublicense Share shall be either
(a) [†] percent ([†]%) for any sublicense for Licensed Products encompassed by valid and
subsisting claim(s) of patent(s) included in the Initial MASP-2 Patents or (b) [†] percent
([†]%) for any sublicense for Licensed Products encompassed by valid and subsisting claim(s)
of patent(s) included in the Other MASP-2 Patents. For

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

	 	 	purposes of clarity, if a sublicense is for a Licensed Product encompassed by valid and subsisting claims of patents included in
both the Initial MASP-2 Patents and the Other MASP-2 Patents, than the Sublicense Share shall
be computed only on the basis of the Other MASP-2 Patents.
	 
	3.3	 	Omeros shall pay Helion Royalty payments and Sublicense Share payments on a quarterly basis
for Net Sales and Sublicense Revenue, respectively, collected during each respective quarter.
Royalty and Sublicense Share payments for each quarter shall be made within [†] of the end of
the quarter. If Omeros is required to use any estimated figures to meet this payment time
frame, Omeros shall note such figures as estimated in an accompanying report and shall adjust
the Royalty and Sublicense Share paid the next quarter when actual figures are available for
the prior quarter. Net Sales, Royalty payments, Sublicense Revenue and Sublicense Share
payments shall be computed based on a conversion from any other denomination to U.S. Dollars
for any revenues received or costs and expenses incurred by Omeros during the relevant
quarter, as provided herein, using the exchange rate published in The Wall Street Journal,
West Coast edition, on the last business day of the applicable calendar quarter. Each
quarterly Royalty and/or Sublicense Share payment shall be accompanied by (a) a report
specifying the source and amount of the Royalty and/or Sublicense Share payment itemized on a
product-by-product basis and country-by-country basis, and (b) the total of all discounts,
returns, credits and commissions deducted from gross amounts to determine Net Sales and/or
Sublicense Revenue.
	 
	3.4	 	Helion reserves the right to employ a certified public accountant to review and reconcile the
directly relevant accounting records and procedures of Omeros as they relate to the
determination of Royalties or Sublicense Share fees during reasonable business hours and no
more than [†], and Omeros agrees to make available at Omeros’ place of business all such
directly relevant accounting records for that purpose within [†] of written request by Helion.
The cost of such review shall be borne by Helion, unless it is found that Omeros under-paid a
quarterly royalty or sublicense revenue fees for any quarter by an amount of [†]% ([†]
percent) or greater, in which case the cost of such review shall be borne by Omeros.
	 
	3.5	 	In the event any Royalty or Sublicense Share payments due are not timely paid by Omeros,
Omeros shall pay to Helion interest charges on such late payments at a rate per annum that is
[†] percent ([†]%) above the then current twelve-month LIBOR rate.
	 
	3.6	 	Notwithstanding anything to the contrary herein, Omeros shall have no obligation to pay any
Royalties or Sublicense Share payments for any Licensed Product based on any patent claim that
has been declared invalid or unenforceable by a court or governmental body of competent jurisdiction or based on any patent claim that is not enforceable in the
jurisdiction(s) where such products are manufactured, used, sold, offered for sale, imported
or distributed.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

	4	 	Milestone Payments
	 
	4.1	 	Omeros shall pay Helion the following one-time milestone payments (each a “Milestone
Payment”) on invoice upon completion of the associated activity (each a “Milestone”) by Omeros
or by a sublicensee of Omeros. Omeros shall provide Helion written notice of the completion
of each Milestone by Omeros or Omeros’ sublicensee within [†] of such Milestone completion.
The amount of each Milestone Payment associated with development or commercial Milestones
shall be determined as follows depending on whether (a) the Licensed Product triggering the
Milestone is encompassed only by subsisting and valid claim(s) of the Initial MASP-2 Patents
or

		(b) the Licensed Product triggering the Milestone is encompassed by subsisting and valid
claim(s) of the Other MASP-2 Patents. If a Milestone (the “Subject Milestone”) is reached
in a country in which neither the Initial MASP-2 Patents or the Other MASP-2 Patents
encompass the Licensed Product, then the corresponding Milestone Payment (the “Subject
Milestone Payment”) is not due, but the Subject Milestone Payment shall thereafter become
due if the Subject Milestone again is reached or any subsequent Milestone is reached in a
country in which either the Initial MASP-2 Patents and/or the Other MASP-2 Patents encompass
the Licensed Product.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

	 	 	 
	Milestone	 	Milestone Payment
	Execution of this Agreement.
	 	[†] US Dollars ($[†])
	Filing of first IND for a Licensed Product
	 	(a) [†] dollars ($[†]), or
	(a) If only the Initial MASP-2 Patents  apply, or
	 	(b) [†] dollars ($[†])
	(b) if the Other MASP-2 Patents apply.
	 	 
	 
	 	 
	Initiation of first Phase 2 study for a
	 	(a) [†] dollars ($[†]), or
	Licensed Product
	 	 
	 
	 	(b) [†] dollars ($[†])
	(a) If only the Initial MASP-2 Patents
apply, or
	 	 
	(b) if the Other MASP-2 Patents apply.
	 	 
	 
	 	 
	Initiation of first Phase 3 study for a
	 	(a) [†] dollars ($[†]), or
	Licensed Product
	 	 
	 
	 	(b) [†] dollars ($[†])
	(a) If only the Initial MASP-2 Patents
apply, or
	 	 
	(b) if the Other MASP-2 Patents apply.
	 	 
	 
	 	 
	First marketing approval
	 	(a) [†] dollars ($[†]), or
	(a) If only the Initial MASP-2 Patents apply, or
	 	(b) [†] dollars ($[†])
	(b) if the Other MASP-2 Patents apply.
	 	 
	 
	 	 
	Second marketing approval for a substantially
	 	(a) [†] dollars ($[†]), or
	different indication
	 	 
	 
	 	(b) [†] dollars ($[†])
	(a) If only the Initial MASP-2 Patents
apply, or
	 	 
	(b) if the Other MASP-2 Patents apply.
	 	 
	 
	 	 
	Net Sales reach [†] dollars (US$[†]) within [†]
	 	[†] dollars ($[†])
	of launch of commercial sales of the Licensed
Product
	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

	5	 	Payment Procedures
	 
	5.1	 	All payments due from Omeros to Helion under this Agreement shall be made by wire transfer to
an account specified by Helion.
	 
	5.2	 	All payments due from Omeros to Helion under this Agreement shall be made in U.S. Dollars,
and all dollar ($) amounts referenced in this Agreement shall be understood to refer to U.S.
Dollars.
	 
	6	 	Reporting and Development Efforts
	 
	6.1	 	Omeros shall on an annual basis deliver to Helion a written progress report detailing the
status of Omeros’ efforts to fund, patent, develop and commercialize one or more Licensed
Products. Helion shall notify Omeros if Helion is dissatisfied with the frequency or detail in
progress reports from Omeros.
	 
	6.2	 	Omeros shall promptly provide Helion with a copy of all sublicenses granted by Omeros in the
Licensed IP for the commercialization of Licensed Products.
	 
	6.3	 	Omeros shall use reasonable efforts, based on reasonable commercial prudence, to develop and
introduce to the market one or more Licensed Products. The reasonable performance of research
and/or development activities, funding efforts, patenting efforts, partnering, sale or
licensing efforts, or regulatory approval efforts related to one or more Licensed Products,
internally at Omeros or a successor-in-interest thereto and/or under contract with a third
party, shall be deemed to be reasonable efforts under this Section. Temporary delays in the
performance of such activities shall not be considered a lack of reasonable efforts so long as
Omeros or a successor-in-interest thereto has not affirmatively announced a decision to
abandon all such activities.
	 
	7	 	Patent Prosecution; [†]; Prior Patent Expenses
	 
	7.1	 	Omeros shall assume responsibility for further prosecution and maintenance of patents and
patent applications within the Licensed IP, at Omeros’ sole expense, in consultation with
Helion.
	 
	7.2	 	Helion shall assist Omeros in the prosecution and maintenance of patents and patent
applications within the Licensed IP without additional compensation but at no cost to Helion,
including without limitation [†] of patents and patent applications included within the
Initial MASP-2 Patents to [†].
	 
	7.3	 	[†].
	 
	7.4	 	If, [†], Helion requests for use outside of the Licensed Field a sublicense(s) from Omeros
under either or both of the exclusive license(s) held by Omeros from the U.K. Medical Research
Council and/or the University of Leicester related to such corrected patent(s) or patent
application(s), Omeros shall grant to Helion such sublicense(s) on an exclusive basis for use
outside of the Licensed Field, each such sublicense to be on terms

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-7-

 

	 	 	commensurate with the license under this Agreement granted to Omeros by Helion to the
Initial MASP-2 Patents.
	 
	7.5	 	Omeros agrees to reimburse Helion for (a) its reasonable out of pocket legal costs for
responding to office actions incurred during the period of August 2009 through December, 2009
in US Patent Application [†] and EP Patent Application [†], not to exceed US $[†] in total and
(b) its reasonable out of pocket legal costs for prosecuting and maintaining other patents and
patent applications within the Licensed IP during the period between January 1, 2010 and the
Effective Date of this Agreement, not to exceed $[†] in total except as authorized in advance
by Omeros; provided, however, that Helion has consulted with Omeros on prosecution and
maintenance actions taken during this time period and Omeros shall not be responsible for the
costs of any actions taken during any period of time in which Helion unreasonably delayed
completion and execution of this Agreement. All costs for reimbursement shall be accompanied
by copies of the law firm invoices for such costs.
	 
	7.6	 	Each party shall continue to own its respective Intellectual Property Rights and licenses to
third party Intellectual Property Rights existing prior to or obtained independently of this
Agreement.
	 
	8	 	Enforcement of Licensed IP
	 
	8.1	 	Omeros shall have the sole right at its discretion to enforce the Licensed IP against third
party infringers, including the initiation of any civil action in Omeros’ name, at Omeros’
sole expense, and any resulting Net Enforcement Proceeds shall belong solely to Omeros without
duty to account to Helion, except for inclusion of the Net Enforcement Proceeds in the Net
Sales. Helion shall assist Omeros in prosecution, maintenance and enforcement of patents and
patent applications within the Licensed IP without additional compensation but at no cost to
Helion. In the event that it is necessary for Omeros to join Helion as a party to any such
civil action, Helion shall join such action for no additional compensation but at no cost to
Helion, and any resulting Net Enforcement Proceeds shall belong solely to Omeros without duty
to account to Helion, except for inclusion of the Net Enforcement Proceeds in the Net Sales.
	 
	8.2	 	If Omeros unreasonably declines to initiate enforcement of any patent within the Licensed IP
against any third party infringer within [†] of a written demand from Helion to do so, then
Helion shall have the sole right at its discretion to enforce such infringed patent against
such third party infringer, including the initiation of any civil action in Helion’s name, at
Helion’s sole cost, in which event any award, judgment, settlement or damages collected shall
belong solely to Helion without duty to account to Omeros.
	 
	8.3	 	Omeros’ obligation to pay Helion Royalty and Sublicense Share payments shall be suspended and
accrued during any period of time that a third party infringer of the Licensed IP is using,
manufacturing, marketing, distributing, selling or offering for sale Licensed Product,
provided that Omeros acts with commercially reasonable diligence to enforce the Licensed IP
against such third party infringer, and Omeros shall be entitled to

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-8-

 

	 	 	deduct any amount of its enforcement costs that are in excess of any awards, judgments,
settlements or damages collected by Omeros from such enforcement against such accrued
Royalty and Sublicense Share payments and any future Royalty and Sublicense Share payments
owed.
	 
	8.4	 	If Helion learns of the infringement of any patent or other Intellectual Property Right
included in the Licensed IP, Helion shall promptly notify Omeros of such infringement and will
provide Omeros with all evidence of infringement in Helion’s possession. Both parties shall
use their best efforts in cooperation with each other to terminate third party infringement
without litigation.
	 
	9	 	Representations, Warranties and Other Obligations of Omeros
	 
	9.1	 	Omeros represents and warrants that it has the requisite corporate power and authority and
the legal right to enter into this Agreement and to perform its obligations hereunder.
	 
	10	 	Representations, Warranties and Other Obligations of Helion
	 
	10.1	 	Helion represents and warrants that it has the requisite corporate power and authority and
the legal right to enter into this Agreement and to perform its obligations hereunder.
	 
	10.2	 	Helion represents and warrants, subject only to any ownership rights that may be claimed by
the U.K. Medical Research Council and/or the University of Leicester in the Initial MASP-2
Patents by virtue of any inventorship by any employee(s) of such institutions, that Helion
holds all rights and free and clear title to the Licensed IP.
	 
	10.3	 	Helion undertakes, represents and warrants that it shall cause Prof. Jens Chr. Jensenius and
Prof. Steffen Thiel to each execute this Agreement to confirm their agreement to be bound to
the same extent as Helion with respect to all relevant provisions of this Agreement.
	 
	10.4	 	Helion represents and warrants that it conveys the license to the Licensed IP and all other
rights conveyed to Omeros under this Agreement free of any and all liens, encumbrances,
licenses or claims, and free of any and all royalty, milestone, fee or other obligations owed
to any third party(ies), including, without limitation, Aarhus University, Prof. Jens Chr.
Jensenius, Prof. Steffen Thiel, Helion Holding ApS, NatImmuneA/S and antibody screening or
development companies.
	 
	10.5	 	Helion warrants that it is not aware of any third party rights that would be infringed as a
result of Omeros’ development of Licensed Products in accordance with the terms of this
Agreement.
	 
	10.6	 	Helion represents and warrants that Helion conveys a clear and unencumbered license to the
Helion Antibodies for all purposes without any restrictions or obligations owed to any third
party individuals and entities that originally generated the Helion Antibodies (“Helion
Antibody Creators”), and Helion will disclose to Omeros the exact process and
materials used to generate the Helion Antibodies and any known third party rights that

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-9-

 

	 	 	are relevant to the Helion Antibodies or the process or materials used to generate the Helion
Antibodies; provided, however, that Helion makes no representation or warranty that the
Helion Antibodies do not infringe any rights unknown to Helion of any third parties, other
than the Helion Antibody Creators, for the generation of antibodies.
	 
	10.7	 	Helion represents, warrants and undertakes that, unless otherwise agreed in writing by
Omeros, it shall neither perform nor sponsor any further research, development or commercial
activity related to MASP-2 within the Licensed Field during the term of this Agreement.
	 
	10.8	 	THE WARRANTIES SET FORTH EXPRESSLY IN THIS AGREEMENT ARE THE SOLE WARRANTIES MADE BY EITHER PARTY TO THE OTHER AND THERE ARE NO OTHER WARRANTIES,
REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, REGARDING THE LICENSED PRODUCTS, THE LICENSED RESEARCH PRODUCTS ,
OR OTHER PRODUCTS, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
	 
	11	 	Confidentiality
	 
	11.1	 	Helion and Omeros hereby affirm and incorporate by reference the terms of the Mutual
Nondisclosure Agreement between the parties dated May 16, 2008 concerning the subject matter
of this Agreement, a copy of which is attached hereto as Exhibit C, except to the
extent that the terms of such nondisclosure agreement may conflict with the terms of this
Agreement, in which case the terms of this Agreement shall prevail. The parties further agree
that the mutual obligations of nondisclosure and non-use set forth in such Mutual
Nondisclosure Agreement shall subsist for a period of five (5) years after the termination of
this Agreement.
	 
	11.2	 	The terms of this Agreement shall be maintained in strict confidence by both Helion and
Omeros, and may not be disclosed by either party without the consent of the other party,
except as may be required under a court order or decree or as required to comply with any
governmental law, rule or regulation, and Omeros may disclose the terms of this Agreement to
Omeros’ current and potential employees, directors, consultants, shareholders, investors and
corporate partners. Helion acknowledges that Omeros is legally required and shall be permitted
without further consent to file a summary of the terms of this Agreement and a copy of this
Agreement with the U.S. Securities and Exchange Commission, provided, however, that Omeros
will in good faith seek to secure confidential treatment for information that it views to be
competitively sensitive, and that Omeros shall be permitted to issue a press release
concerning the entry into and overall terms of this Agreement, the disclosure of which shall
be no broader than that disclosed to the U.S. Securities and Exchange Commission.
	 
	12	 	Release of any Pre-existing Claims
	 
	12.1	 	Omeros and Helion each releases the other party and their respective licensors and licensees
from any and all claims arising prior to the Effective Date of this Agreement.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-10-

 

	13	 	Indemnification and Limitation of Liability
	 
	13.1	 	Each party (the “Indemnifying Party”) shall indemnify, hold harmless and defend the other
party and its employees, officers, directors, consultants and agents (the “Indemnified Party”)
against any and all claims, suits, losses, liabilities, damages, costs, fees, and expenses
(“Claims”) resulting from or arising directly out of the Indemnifying Party’s breach of any
representation, warranty or obligation under this Agreement, or the Indemnifying Party’s
exercise of the rights and obligations under this license or any sublicense, except that such
obligation to indemnify, hold harmless and defend shall not extend to any Claims to the extent
such Claims result from or arise directly from the negligence or misconduct of the Indemnified
Party. This indemnification does not include any indemnity in relation to product performance
or product liability.
	 
	13.2	 	Without limitation of each party’s indemnification obligations under the preceding
Subsection, neither party shall be liable under this Agreement to another party for any
incidental, consequential or special damages.
	 
	14	 	Term and Termination
	 
	14.1	 	Unless terminated earlier as set forth in Subsection 14.2 herein below, this Agreement shall
subsist so long as there is any valid and subsisting claim included within any patent, utility
model or inventor’s certificate within the Licensed IP or pending patent application within
the Licensed IP.
	 
	14.2	 	Either party may terminate this Agreement at any time in the event that the other party
breaches any material obligation of this Agreement by first submitting written notice of
breach to the breaching party, which breach is not substantially cured within ninety (90) days
of the receipt of such notice, followed by written notice of termination then being sent to
the breaching party.
	 
	14.3	 	The provisions of Sections and Subsections 1, 3 (only with respect to payments coming due
prior to termination), 4 (only with respect to payments coming due prior to termination),
9-13, 14.3, 15 and 16 shall survive expiration or termination of this Agreement for the period
set forth therein or, if no period is set forth therein, then indefinitely.
	 
	15	 	Use of Names
	 
	15.1	 	Nothing contained in this Agreement confers any right to either party to use in advertising,
publicity, or other promotional activities any name, trade name, trademark, or other
designation of the other party hereto, and neither party shall make such use without the prior
written consent of the other party, provided however Omeros may through written, oral or
electronic communication disclose the existence of this Agreement and the name of Helion to Omeros’ current
and potential employees, directors, consultants, shareholders, investors and corporate partners, as required to

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-11-

 

	 	 	comply with any governmental law, rule or regulation, and in a press release to be issued by Omeros regarding this
Agreement. Omeros shall provide Helion with an advance draft of its press release referring to this Agreement
for review and comment by Helion.
	 
	16	 	Miscellaneous 
	 
	16.1	 	This Agreement including all appendices and exhibits attached thereto or incorporated by
reference therein constitutes the entire understanding of the parties hereto regarding the
subject matter of this Agreement, and no other representation, agreement, promise or
undertaking altering, modifying, taking from or adding to the terms of this Agreement shall
have any effect unless the same is reduced to writing and duly executed by the parties hereto.
In the event of any conflict between the main body of this Agreement and any attachments
thereto or documents incorporated by reference therein, the provisions of the main body of
this Agreement shall control.
	 
	16.2	 	Either party’s failure to enforce any provision of this Agreement will not be considered a
waiver of future enforcement of that or any other provision.
	 
	16.3	 	The laws of the state of Delaware, United States, without regard to its conflict-of-laws
provisions, shall govern this Agreement, its interpretation and its enforcement, and any
disputes arising out of or related to this Agreement.
	 
	16.4	 	Any civil action prosecuted or instituted by either party with respect to any matters arising
out of or related to this Agreement shall be brought in the United States District Courts
located in the state of Delaware, United States, and each party hereby consents to the sole
and exclusive jurisdiction and venue of such courts for such purposes.
	 
	16.5	 	In the event that it is necessary for either party of this Agreement to take legal action to
enforce any of the terms, conditions or rights contained herein, or to defend any such action,
then the prevailing party in such action shall be entitled to recover from the other party all
reasonable attorneys fees, costs and expenses related to such legal action.
	 
	16.6	 	In the event that any portion of this Agreement is held invalid or unenforceable by a court
of law, that provision will be construed and reformed to permit enforcement of the provision
to the maximum extent permissible consistent with the parties’ original intent, and if such
construction is not possible, such provision shall be struck from this Agreement, and the
remainder of the Agreement shall remain in full force and effect as if such provision had
never been part of this Agreement.
	 
	16.7	 	For the purposes of this Agreement, the parties hereto are independent contractors, and
nothing in this Agreement shall be construed to place them in the relationship of partners,
principal and agent, employer/employee or joint venturers. Except as provided expressly
herein, each party agrees that it shall have no authority to bind or obligate the other party,
nor shall any party hold itself out as having such authority.
	 
	16.8	 	Neither party will be liable for failure or delay in performing any obligation under this
Agreement, or will be considered in breach of this Agreement, if such failure or delay is

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-12-

 

	 	 	due to a natural disaster or any cause reasonably beyond such party’s control, provided that such
party resumes performance as soon as possible following the end of the event that caused such
delay or failure of performance.
	 
	16.9	 	Neither party may assign this Agreement, or any obligation or right under this Agreement, in
whole or in part, without the other party’s prior written consent, which consent will not be
unreasonably withheld. This Section shall not be construed in any way to limit Omeros’ rights
to grant, at Omeros’ sole discretion, sublicenses hereunder. Helion consents to Omeros’
assignment of this Agreement in whole or in part in connection with the merger, consolidation
or transfer of all or substantially all of that portion of Omeros’ assets to which this
Agreement relates. Subject to these restrictions, this Agreement will be binding upon and
will inure to the benefit of the parties’ permitted successors and assignees.
	 
	16.10	 	Any notice required or permitted to be given hereunder by either party shall be in writing
and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested,
postage prepaid, (c) sent by an internationally recognized courier service guaranteeing
next-day delivery, charges prepaid, or (d) delivered by e-mail (with the original promptly
sent by an internationally recognized courier service guaranteeing next-day delivery, charges
prepaid) to the e-mail address(es) of the other party set forth below, or at such other
addresses as may from time to time be furnished by similar notice by either party. The
effective date of any notice hereunder shall be the date of receipt by the receiving party.

	 	 	 	 	 

	 
	 	If to Omeros:	 	If to Helion:
	 
	 	 	 	 
	 
	 	Omeros Corporation	 	Helion Biotech ApS
	 
	 	1420 Fifth Avenue, Suite 2600	 	Egholmvej 10
	 
	 	Seattle, WA  98101	 	2720 Vanløse
	 
	 	U.S.A.	 	Denmark
	 
	 	 	 	 
	 
	 	Attention:  CEO	 	Attention:  CEO
	 
	 	And copy to: General Counsel	 	 
	 
	 	 	 	 
	 
	 	E-mail: [†]	 	E-mail:  [†]
	 
	 	with a copy to [†]	 	with a copy to [†]
	 
	 	Phone:  206. 676.5000	 	Phone:  +[†]

	16.11	 	This Agreement may be executed in one or more counterparts and by facsimile, each of which
will be considered an original, and all of which will constitute the same instrument.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-13-

 

     IN WITNESS WHEREOF, Omeros and Helion have each acknowledged and accepted this Agreement by
causing it to have been signed by their respective duly authorized officials.

	 	 	 	 	 	 	 	 
	OMEROS CORPORATION	 	HELION BIOTECH APS	 
	 
	 	 	 	 	 	 	 
	By:

	 	/s/ Gregory A. Demopulos
	 	By:
	 	/s/ Jeppe Vesti Christensen	 
	 

	 	 
	 	 	 	 	 
	 	 
	Name:  Gregory A. Demopulos, M.D.
	 	 	 	Name:  Jeppe Vesti Christensen	 
	 

	 	Title:  Chairman & CEO
	 	 
	 	Title:  CEO	 
	 
	 	 	 	 	 	 	 
	Date:  April 23, 2010
	 	Date:  April 9, 2010	 
	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	/s/ Per Fischer
	 	 	 	 	 	 	Per Fischer
	 	 	 	 	 	 	Chairman April 9, 2010

The above Exclusive License Agreement is acknowledged by the undersigned inventors, who agree to
abide by and comply with the terms for Helion set forth therein to the same extent as Helion.

	 	 	 	 	 	 	 	 

	JENS CHR. JENSENIUS	 	STEFFEN THIEL
	 
	 	 	 	 	 	 
	Signed:

	 	/s/ Jens Chr. Jensenius
	 	Signed:
	 	/s/ Steffen Thiel
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	12/4 — 2010
	 	Date:
	 	12/4 — 2010

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-14-

 

EXHIBIT A

To the Exclusive License Agreement

Between Omeros Corporation and Helion Biotech

INITIAL MASP-2 PATENTS

     The “Initial MASP-2 Patents” shall include the US Patents and Patent Applications listed below
on this Exhibit A as well as all patents issuing therefrom, all reissued patents and patent
applications, reexamined patents and patent applications, divisional patents and patent
applications, continuation patents and patent applications based thereon or claiming priority
therefrom, and all other patents and patent applications worldwide claiming priority from or
corresponding to US Patent Applications [†] filed [†] or [†] filed [†] or PCT International
Application [†] (to the extent claiming subject matter originally disclosed in US Patent
Applications [†] or [†]).

	 	 	 	 	 

	 

	 	Helion Reference:
	 	[†]
	 

	 	Description:
	 	[†]
	 

	 	Patent Application no.:
	 	[†]
	 

	 	Filed:
	 	[†]
	 

	 	Priority:
	 	[†]
	 

	 	Issued Patent:
	 	[†]
	 
	 	 	 	 
	 

	 	Helion Reference:
	 	[†]
	 

	 	Description:
	 	[†]
	 

	 	Patent Application no.:
	 	[†]
	 

	 	Filed:
	 	[†]
	 

	 	Priority:
	 	[†]
	 

	 	Issued Patent:
	 	[†]
	 
	 	 	 	 
	 

	 	Helion Reference:
	 	[†]
	 

	 	Description:
	 	[†]
	 

	 	Patent Application no.:
	 	[†]
	 

	 	Filed:
	 	[†]
	 

	 	Priority:
	 	[†]
	 

	 	Issued Patent:
	 	[†]
	 
	 	 	 	 
	 

	 	Helion Reference:
	 	[†]
	 

	 	Description:
	 	[†]
	 

	 	Patent Application no.:
	 	[†]
	 

	 	Filed:
	 	[†]
	 

	 	Priority:
	 	[†]
	 

	 	Issued Patent:
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-15-

 

	 	 	 	 	 

	 

	 	Helion Reference:
	 	[†]
	 

	 	Description:
	 	[†]
	 

	 	Patent Application nos.:
	 	[†]
	 

	 	Filed:
	 	[†]
	 

	 	Priority:
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-16-

 

EXHIBIT B

To the Exclusive License Agreement

Between Omeros Corporation and Helion Biotech

OTHER MASP-2 PATENTS

     The “Other MASP-2 Patents” shall include all other patents and patent applications that are
not included in the Initial MASP-2 Patents in which Helion holds rights related to MASP-2 or other
inhibitors or methods of inhibiting lectin-mediated activation of the complement system including,
without limitation, the patents and patent applications listed below in this Exhibit B as well as
all patents issuing therefrom, all reissued patents and patent applications, reexamined patents and
patent applications, divisional patents and patent applications, continuation patents and patent
applications based thereon or claiming priority therefrom, and all other patents and patent
applications worldwide claiming priority from or corresponding to [†] (to the extent not claiming
subject matter originally disclosed in US Patent Applications [†] or [†]) or [†].

	 	 	 	 	 

	 

	 	Helion Reference:
	 	[†]
	 

	 	Description:
	 	[†]
	 

	 	Patent Application nos.:
	 	[†]
	 

	 	Filed:
	 	[†]
	 

	 	Priority:
	 	[†]
	 
	 	 	 	 
	 

	 	Helion Reference:
	 	[†]
	 

	 	Description:
	 	[†]
	 

	 	Patent Application no.:
	 	[†]
	 

	 	Filed:
	 	[†]
	 

	 	Priority:
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-17-

 

EXHIBIT C

To the Exclusive License Agreement

Between Omeros Corporation and Helion Biotech

MUTUAL CONFIDENTIALITY AGREEMENT

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-18-

 

OMEROS CORPORATION

MUTUAL CONFIDENTIALITY AGREEMENT

     This Confidentiality Agreement (this “Agreement”) is entered into as of May 16, 2008 by and
between OMEROS CORPORATION (“Omeros”) and HELION BIOTECH (“Helion”).

In the course of business negotiations and transactions between the parties hereto and subject to
the procedures set forth in Section 1 below, either or both parties and agents thereof (including
without limitation, attorneys and consultants representing the parties) may disclose certain
confidential and proprietary information for the sole purpose of evaluating a potential business
relationship and/or performing in accordance with any separate agreement that may be reached
between the parties that does not supersede this Agreement (“Purpose”). The parties want to provide
for the protection of any such confidential and proprietary information disclosed by one party (the
“disclosing party”) to which the other party receiving the information (the “recipient”) has access
in accordance with Section 1 below. In consideration of the above premises, the parties agree:

	1.	 	Procedure for Disclosure. Before disclosing any Confidential Information, (a)
the disclosing party shall provide recipient with a non-confidential summary of the
proposed Confidential Information, thus enabling the recipient to decide whether the
recipient wants to receive such Confidential Information; and (b)
the recipient shall confirm in writing whether they accept receipt of such Confidential
Information. Unless recipient confirms acceptance of receipt of such Confidential
Information, notwithstanding anything contrary in this Agreement, the disclosed information
shall be deemed non-confidential and shall not be protected as Confidential Information
hereunder. Each party hereby agrees in advance to accept in confidence from the other party
Confidential Information regarding license or acquisition agreements related to MASP-2 into
which each party has entered with third parties prior to the execution of this Agreement
(“MASP-2 Historical Information”) and discussions, proposals, term sheets and draft
agreements concerning a potential separate agreement between the parties related to the
licensing or acquisition of rights related to MASP-2 (“Proposals”). All Confidential
Information shall be disclosed in written form, which may be in hard copy or electronic
format, and marked “Confidential”, or if disclosed orally shall be summarized in written
form, marked “Confidential” and provided to the recipient within thirty (30) days of oral
disclosure.
	 
	2.	 	Covenant Not to Disclose to Third Party. For a period of five years from the date of last
disclosure hereunder, the recipient of any Confidential Information will not at any time
disclose or otherwise make known or available to any person, firm, corporation or other
entity, or use for its own account or for any purpose other than the Purpose or as otherwise
set forth herein, any Confidential

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-19-

 

	 	 	Information disclosed by the other party prior to or during the term of this Agreement,
without the express prior written consent of the disclosing party. Helion hereby consents
to Omeros’ sharing of Helion’s Confidential Information to the extent that Helion’s
Confidential Information relates to MASP-2 Historical Information and relative rights
attendant thereto or Proposals, on a need to know basis, to the UK Medical Research Council
and the University of Leicester under obligations of confidentiality consistent with this
Agreement. The recipient shall utilize reasonable procedures to safeguard Confidential
Information from unauthorized use, reproduction and disclosure and under secure conditions,
including releasing Confidential Information only to employees, consultants, licensors or
professional advisors who have agreed to abide by the recipient’s obligations hereunder on
a “need-to-know” basis.
	 
	3.	 	Confidential Information.
	 
	3.1	 	For information disclosed by Omeros in accordance with Section 1, “Confidential Information”
means any and all information provided by Omeros related to MASP-2 Historical Information or
Proposals or relating to the following technology that was licensed, acquired, developed or
are owned and/or held by Omeros: methods, antibodies and other agents and compositions for the
inhibition of the complement immune system, including without limitation information developed
by Omeros and/or obtained from the University of Leicester, the UK Medical Research Council
and/or Fukushima Medical University regarding MASP-2 or MAp19 as well as methods for
inhibiting the same; and includes, without limitation, research and development information,
know-how, legal analysis, inventions, trade secrets, technical data, knock-out and knock-in
mouse strains, gene expression profiles, behavioral and physiological assays, phenotypes, cell
lines, cellular, biochemical and chemical assays, chemical structures, formulae, treatment
methods, clinical trial design criteria, protocols, case report forms (blank or including
patient data), investigators’ brochures, drawings, designs, models, samples, processes,
chemistry, manufacturing and controls information, regulatory information, and any type of
product development, business or marketing plans or strategies or financial information.
	 
	 	 	For information disclosed by Helion in accordance with Section 1, “Confidential
Information” means any and all information provided by Helion related to
MASP-2 Historical Information or Proposals or relating to the following technology that was
acquired, licensed, developed or is owned and/or held by Helion: methods, antibodies and
other agents and compositions for the inhibition of MASP-2 or for the treatment of MASP-2
deficiency disorders; and includes without limitation, research and development
information, know-how, legal analysis, inventions, trade secrets, technical data, knock-out
and knock-in mouse strains, gene expression profiles, behavioral and physiological assays,
phenotypes, cell lines, cellular, biochemical and chemical assays, chemical structures,
formulae, treatment methods, clinical trial design criteria, protocols, case report
forms (blank or including patient data), investigators’ brochures,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-20-

 

	 	 	drawings, designs, models, samples, processes, chemistry, manufacturing and controls information, regulatory
information, and any type of product development, business or marketing plans or strategies
or financial information.
	 
	3.2	 	Confidential Information does not include information that the recipient can establish:
	 
	3.2.1	 	is or becomes generally available to the public other than as a result of a disclosure by
the recipient;
	 
	3.2.2	 	was in the possession of the recipient prior to its being furnished to the recipient under
this Agreement, provided that the source of such information was not known to the recipient to
be bound by a confidentiality agreement with, or other contractual, legal, or fiduciary
obligation of confidentiality to the disclosing party or any other party with respect to such
information and that such prior possession can reasonably be proven by the recipient by
written records;
	 
	3.2.3	 	becomes available to the recipient on a non-confidential basis from a source other than the
disclosing party, provided that such source is not bound by a confidentiality agreement with,
or other contractual, legal, or fiduciary obligation of confidentiality to the disclosing
party or any other party with respect to such information;
	 
	3.2.4	 	becomes available to the recipient through discovery procedures in any civil action or
arbitration between the parties; or
	 
	3.2.5	 	was independently developed by the recipient without reference to the Confidential
Information, provided that such independent development can reasonably be proven by the
recipient by written records.
	 
	3.3	 	If the recipient is required by order of a court of law, administrative agency, or other
governmental body to disclose any of the Confidential Information to any third party, the
recipient will promptly provide the disclosing party with reasonable advance written notice if
at all possible to enable the disclosing party the opportunity to seek a protective order or
to otherwise prevent or limit such legally required disclosure, will use reasonable efforts to
cooperate with the disclosing party to obtain such protection, and will disclose only the
legally required portion of the Confidential Information. Any such legally required disclosure
will not relieve recipient from its obligations under this Agreement to otherwise limit the
disclosure and use of such information as Confidential Information.
	 
	4.	 	Limitations on Use. In further recognition of the value of Confidential Information, the
recipient acknowledges that it shall not engage in the reproduction of Confidential
Information through the techniques of “reverse engineering”. The recipient shall not make any
use, either directly or indirectly, of any Confidential Information to which the recipient has
been, is or will be exposed, except in the ordinary course of business pursuant to this Agreement for

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-21-

 

	 	 	the Purpose or as may be expressly authorized herein below or in a separate specific written
agreement between the parties. Nothing in this Agreement shall be construed as giving
recipient any license or other right under any intellectual property lawfully owned or held
by the disclosing party or as an admission as to the scope of any such rights owned or held
by the disclosing party. Neither party shall disclose the existence and nature of this
Agreement or the fact that it is evaluating the other party’s Confidential Information or
that discussions related to Proposals are occuring pursuant to this Agreement, except that
such disclosure to a party’s present employees, consultants, officers, directors,
shareholders, bankers and investors, and to present and potential investors, bankers and
business partners pursuant to due diligence reviews, is permitted if such persons have
agreed to abide by the recipient’s obligations hereunder, and disclosure of the nature and
existence of this Agreement and that discussions related to Proposals are occurring
pursuant to this Agreement by Omeros to the US Securities and Exchange Commission shall be
permitted. Neither party shall use the name of the other party in any publicity or
advertising without that party’s prior written approval.
	 
	5.	 	Return of Confidential Information. When requested by the disclosing party or at the
termination of the relationship giving rise to this Agreement, whichever first occurs, the
recipient immediately shall deliver all Confidential Information and all copies thereof in its
possession or in the possession of its employees, provided that the recipient’s legal counsel
may retain one archival copy of the Confidential Information.
	 
	6.	 	Permitted Use of Information. Notwithstanding any restrictions in Sections 2 or 4, recipient
shall be entitled to use the disclosing party’s Confidential Information in any civil action
or arbitration between the parties, provided that (a) the disclosing party shall be entitled
to seek a protective order concerning disclosure of any such Confidential Information to third
parties and the recipient shall cooperate in good faith with any reasonably requested
protective order, (b) no disclosure to the recipient of any attorney-client or attorney-work
product privileged information by the disclosing party under this Agreement shall be asserted
or contended to be deemed a waiver of such privilege and any such privileged information shall
not be admissible in any civil action or arbitration solely by virtue of having been disclosed
under this Agreement, and (c) the recipient shall not use any Confidential Information
obtained by recipient from the disclosing party solely under this Agreement as the basis for
seeking any preliminary injunctive relief.
	 
	7.	 	[†].
	 
	 	 	8. Specific Performance. The parties acknowledge that (a) the covenants set forth in this
Agreement are essential elements of the transactions contemplated in this Agreement and that, but
for the agreement to comply with such covenants, the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-22-

 

	 	 	parties would not have entered into such transactions, and that the parties have consulted with, or have
had the opportunity to consult with, counsel and have been advised in all respects
concerning the reasonableness of such covenants as to scope and limit of time; (b) the
disclosing party will not have any adequate remedy at law if the recipient violates this
Agreement or fails to perform any of its other obligations hereunder; and (c) the
disclosing party shall have the right, in addition to any other rights it may have, to
obtain in any court of competent jurisdiction temporary, preliminary and permanent
injunctive relief to restrain any breach, threatened breach, or otherwise to specifically
enforce any of such covenants or any other obligations of the recipient if the recipient
fails to perform any of its obligations under this Agreement.
	 
	9.	 	Term. This Agreement and the obligations of nondisclosure and nonuse set forth herein shall
terminate five (5) years after the date of the last disclosure of Confidential Information
under this Agreement, except that termination of the obligation of nonuse under this Agreement
shall not permit use of the Confidential Information that would be in infringement of patent
rights. Prior to termination of this Agreement, either party may deliver written notice to the
other party that it no longer wishes to receive Confidential Information under this Agreement,
after receipt of which any information subsequently sent in writing or orally disclosed by
either party shall be deemed non-confidential.
	 
	10.	 	Miscellaneous. This Agreement shall be binding upon and inure to the benefit of the parties’
successors and assigns. The waiver of any breach of any provision of this Agreement or failure
to enforce any provision hereof shall not operate or be construed as a waiver of any
subsequent breach by any party. The invalidity of all or any part of any section of this
Agreement shall not render invalid the remainder of this Agreement or the remainder of such
section. If any provision of this Agreement is so broad as to be unenforceable, such provision
shall be interpreted to be only so broad as is enforceable. In any litigation or arbitration
arising out of or related to this Agreement, the substantially prevailing party will be
entitled to recover all reasonable costs and attorneys’ fees, including costs and fees on
appeal. The provisions of this Agreement shall not be construed as limiting any rights or
remedies that either party may otherwise have under the applicable law.
	 
	11.	 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws
of the State of Delaware, USA, without giving effect to any conflict of laws principles that
would result in the application of the laws of another jurisdiction. The parties agree that
the sole and exclusive jurisdiction for any disputes arising under or related to this
Agreement shall be in the federal courts of the United States.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-23-

 

	 	 	 	 	 
	 	OMEROS CORPORATION

 	 
	 	By  	/s/ Marcia Kelbon
 	 
	 	 	Printed name Marcia Kelbon  	 
	 	 	Its V.P., Patent & General Counsel 	 
	 
	 	HELION BIOTECH

 	 
	 	By  	/s/ Jeppe Christensen
 	 
	 	 	Printed name Jeppe Christensen 	 
	 	 	Its CEO 	 
	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-24-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]